Crohn's disease and ulcerative colitis are common inflammatory bowel diseases.
They affecting nearly 1 in 100 people in the UK, across Europe and N America, with rapidly rising incidence rates across the world.
Impact on patients can be very profound - physical symptoms, psychosocial features and the long term complications of the disease and the drugs. But it is the impact on everyday life that can be most significant for the individual.
We have a series of unmet needs in 2022 from raising awareness and ensuring equity of care to the need for new therapies, better monitoring systems and a holistic approach that results in meaningful healing.
Video Editing by @IBDNathan Nathan Constantine-Cooke
Graphic design by @ErikRva
[ Ссылка ] ATOMIC IBD
[ Ссылка ]
[ Ссылка ]
[ Ссылка ]...
[ Ссылка ]
#atomicIBD #crohnsdisease #crohn #IBD #inflammatoryboweldisease #colitis #ulcerativecolitis #UC @crohnsandcolitisuk
PROFESSOR CHARLIE W LEES FRCP(Ed) PhD
Charlie is Professor of Gastroenterology at the University of Edinburgh, a UK Research and Innovation Future Leaders Fellow (UKRIFLF) and Consultant Gastroenterologist in the Edinburgh IBD Unit. His clinical, teaching and research interests have been focused on inflammatory bowel disease (IBD) since 2003. He was awarded his PhD in the Genetics of IBD and the prestigious UEG Rising Star award in Gastroenterology, both in 2009. Following this he spent 10 years working as a full-time consultant gastroenterologist leading an increasingly busy and complex IBD clinic.
In 2019 Charlie was awarded a personal fellowship from UKRI - worth £1.7m - that enabled his transition to full-time academic gastroenterology. His research team are based in the Centre for Genomics and Experimental Medicine within the Institute of Genetics and Cancer in Edinburgh.
Charlie’s core mission is to improve outcomes for people living with IBD.
His team are working on predicting outcomes in IBD, using routinely collected NHS data (the Lothian IBD Registry) and dedicated multi-modal prospective cohorts to build predictive models.
He is Chief Investigator of the PREdiCCt study, which has recruited 2650 patients in clinical remission with detailed baseline phenotyping (clinical, psycho-social, lifestyle, environmental, dietary, microbiome and genomics) and a minimum of 24 months longitudinal follow-up.
Conflicts of Interest
Professor Charlie Lees has acted as a speaker and/or consultant to Abbvie, Janssen, Takeda, Pfizer, Galapagos, GSK, Gilead, Vifor Pharma, Ferring, Dr Falk, BMS, Boehringer Ingelheim, Novartis, Sandoz, Celltrion, Fresnius Kabi, Tillotts, Trellus Health and Iterative Scopes.
